CoMentis, Inc. engages in the discovery and development of small-molecule drugs to treat Alzheimer's disease, age-related macular degeneration, and cognitive disorders. The company has fundamental technology platforms that include beta-secretase inhibitors for the treatment of Alzheimer's disease; and nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders. It also has various product development programs, such as ATG-3, an anti-angiogenesis compound for neovascular AMD; CTS-21166, an active beta-secretase inhibitor for Alzheimer's disease; and GTS-21, an oral agonist of the nACh receptor for ADHD, and next generation agonists of the nACh receptor in preclinical development. The company was founded as Athenagen, Inc. in 2005 and changed its name to CoMentis, Inc. in 2007. CoMentis, Inc. is based in South San Francisco, California.